Nymox Pharmaceutical Corporation has announced that the company's lead development drug, NX-1207, has been shown to significantly reduce hepatocellular carcinoma (HCC) in animals.
During experimental studies, the cancers were significantly reduced in size after just two local injections of NX-1207. The rodents in the studies had transplanted human HCC, a standard model for cancer research.
The company now intends to advance NX-1207 into human clinical trials for the treatment of HCC.
NX-1207 used in these studies is a different formulation and a higher dosage from that of NX-1207 used to treat benign prostatic hyperplasia (BPH).
NX-1207 is in Phase III development for the treatment of BPH.
The drug has been successful in a series of blinded controlled multi-centre US clinical trials where it has been found to produce improvements that are about double that reported for approved BPH drugs.